Arbutus Biopharma Co. (ABUS) Receives $18.00 Consensus Price Target from Analysts

Arbutus Biopharma Co. (NASDAQ:ABUS) has earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $14.75.

Several research analysts have recently commented on ABUS shares. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a report on Wednesday, September 13th. ValuEngine upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Zacks Investment Research upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday. Leerink Swann reiterated a “market perform” rating and set a $5.00 price target (up previously from $4.00) on shares of Arbutus Biopharma in a research report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Arbutus Biopharma in a research report on Wednesday, September 20th.

Shares of Arbutus Biopharma (ABUS) traded up $0.30 on Monday, hitting $6.15. 99,700 shares of the stock traded hands, compared to its average volume of 234,595. Arbutus Biopharma has a 12 month low of $2.35 and a 12 month high of $8.25. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08.

In related news, insider Michael J. Sofia sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $3.70, for a total transaction of $111,000.00. Following the sale, the insider now owns 1,563,403 shares in the company, valued at approximately $5,784,591.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael J. Sofia sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The disclosure for this sale can be found here. Company insiders own 10.00% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Arbutus Biopharma by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares in the last quarter. Bank of Montreal Can boosted its position in Arbutus Biopharma by 1.9% in the second quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares in the last quarter. OxFORD Asset Management LLP boosted its position in Arbutus Biopharma by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 39,436 shares in the last quarter. Renaissance Technologies LLC boosted its position in Arbutus Biopharma by 785.1% in the first quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Arbutus Biopharma in the second quarter valued at approximately $478,000. Hedge funds and other institutional investors own 66.99% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/11/11/arbutus-biopharma-co-abus-receives-18-00-consensus-price-target-from-analysts.html.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply